Company intelligence
Liquidia Corporation
A biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. Liquidia has developed YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Liquidia is also developing L606, an investigational liposomal formulation of treprostinil administered twice-daily with a short-duration next-generation nebulizer, for use in North America. The subsidiary Liquidia PAH provides for the commercialization of pharmaceutical products to treat pulmonary disease, such as generic Treprostinil Injection.
Verified activity
Signals from Liquidia Corporation
9 published signals
Presence & Recognition
Liquidia Corporation Medical Affairs and Clinical Development teams are onsite at Booth Q07 at the ERSCongress in Barcelona, Spain, from September 5 to 9.
Reported by Liquidia Corporation
People
Liquidia Corporation is hiring a new Senior Quality Associate in Morrisville, North Carolina.
Reported by Liquidia Corporation
Presence & Recognition
Liquidia Corporation is exhibiting at the ERS Congress 2026 Medical Affairs booth at booth Q07 on September 5-9.
Reported by Liquidia Corporation
People
Liquidia Corporation is hiring a new Manager for Legal Operations in the United States.
Reported by Liquidia Corporation
People
Liquidia Corporation is hiring a new Senior Manager Regulatory Affairs in the United States.
Reported by Liquidia Corporation
Research & Knowledge
Liquidia Corporation plans to initiate RE-WARM, a Phase 2a, randomized, open-label, dose-finding study of YUTREPIA in SSc-RP in the fourth quarter of 2026.
Reported by Liquidia Corporation
Legal & Regulatory
Liquidia Corporation announced that the FDA has granted Fast Track designation to YUTREPIA for the treatment of Raynaud's phenomenon associated with systemic sclerosis.
Reported by Liquidia Corporation
Presence & Recognition
Liquidia Corporation is attending the European Respiratory Society (ERS) Congress 2026 in Barcelona.
Reported by Liquidia Corporation
Presence & Recognition
Liquidia Corporation will present at the Wells Fargo 21st Annual Healthcare Conference in Boston, Massachusetts, on September 8, 2026, with Michael Kaseta and Jason Adair providing an update on the company's business during a fireside chat.
Reported by Liquidia Corporation